IO Biotech Yönetim

Yönetim kriter kontrolleri 1/4

IO Biotech CEO'su MBZ Zocca, Jan2015 tarihinde atandı, in görev süresi 9.92 yıldır. in toplam yıllık tazminatı $ 1.65M olup, şirket hissesi ve opsiyonları dahil olmak üzere 32.9% maaş ve 67.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.097% ine doğrudan sahiptir ve bu hisseler $ 56.93K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.7 yıl ve 3.2 yıldır.

Anahtar bilgiler

MBZ Zocca

İcra Kurulu Başkanı

US$1.6m

Toplam tazminat

CEO maaş yüzdesi	32.9%
CEO görev süresi	9.9yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	1.7yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

MBZ Zocca'un ücretlendirmesi IO Biotech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$90m
Jun 30 2024	n/a	n/a	-US$88m
Mar 31 2024	n/a	n/a	-US$88m
Dec 31 2023	US$2m	US$541k	-US$86m
Sep 30 2023	n/a	n/a	-US$80m
Jun 30 2023	n/a	n/a	-US$74m
Mar 31 2023	n/a	n/a	-US$71m
Dec 31 2022	US$734k	US$515k	-US$71m
Sep 30 2022	n/a	n/a	-US$74m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$87m
Dec 31 2021	US$8m	US$399k	-US$75m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$54m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$409k	US$307k	-US$15m

Tazminat ve Piyasa: MBZ 'nin toplam tazminatı ($USD 1.65M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 642.50K ).

Tazminat ve Kazançlar: MBZ şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

MBZ Zocca (57 yo)

9.9yrs

Görev süresi

US$1,645,088

Tazminat

Dr. Mai-Britt Zocca, Ph D, also known as MBZ, was also the Founder and Chief Executive Officer of Onconox ApS since July 2011 until May 2019. She served as Director at Valo Therapeutics Ltd since June 2020...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mai-Britt Zocca	Founder	9.9yrs	US$1.65m	0.097% $ 56.9k
Devin Smith	Secretary	1.9yrs	US$917.30k	0.0075% $ 4.4k
Qasim Ahmad	Chief Medical Officer	1.4yrs	US$920.76k	Veri yok
Inge Svane	Founder & Clinical Advisor	no data	Veri yok	Veri yok
Mads Andersen	Co-Founder & Scientific Advisor	no data	Veri yok	Veri yok
Anders Ljungqvist	Founder	no data	Veri yok	Veri yok
Per Straten	Founder	no data	Veri yok	Veri yok
Amy Sullivan	Chief Financial Officer	2.2yrs	US$904.15k	0.11% $ 66.2k
Eric Faulkner	Chief Technical Officer	1.4yrs	Veri yok	Veri yok
Daniel Mannix	Senior Vice President of Regulatory Affairs	2.9yrs	Veri yok	Veri yok
Faical Miyara	Chief Business Officer	less than a year	Veri yok	Veri yok
Marjan Shamsaei	Senior VP of Commercial Development & Portfolio Lead	less than a year	Veri yok	Veri yok

1.7yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: IOBT 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mai-Britt Zocca	Founder	3.2yrs	US$1.65m	0.097% $ 56.9k
Inge Svane	Founder & Clinical Advisor	no data	Veri yok	Veri yok
Mads Andersen	Co-Founder & Scientific Advisor	no data	Veri yok	Veri yok
David Smith	Independent Director	2.8yrs	US$124.17k	0% $ 0
K. Hirth	Independent Chairman	8.3yrs	US$145.75k	0% $ 0
Christian Elling	Independent Director	9yrs	US$114.14k	0% $ 0
Kathleen Glaub	Independent Director	6.6yrs	US$133.00k	0% $ 0
Alexander Maximiliaan Eggermont	Sr. Clinical Advisor & Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Kapil Dhingra	Strategic Advisory Board Member	no data	Veri yok	Veri yok
Helen Collins	Independent Director	1.1yrs	US$52.48k	0% $ 0
Heidi Hunter	Independent Director	1.3yrs	US$112.61k	0% $ 0

3.2yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IOBT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

IO Biotech Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors

IO Biotech, Inc., Annual General Meeting, Jun 06, 2024

IO Biotech Announces Marjan Shamsaei as Senior Vice President

IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer

High number of new directors

IO Biotech Appoints Helen Collins, Md, to Its Board of Directors

Recent updates

IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-Line Treatment of Advanced Head and Neck Cancer

Price target decreased by 13% to US$8.50

IO Biotech, Inc. Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

New major risk - Financial position

New minor risk - Share price stability

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors

IO Biotech, Inc., Annual General Meeting, Jun 06, 2024

New minor risk - Market cap size

IO Biotech Announces Marjan Shamsaei as Senior Vice President

IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103

IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer

IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting

New major risk - Revenue and earnings growth

New minor risk - Market cap size

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

High number of new directors

IO Biotech Appoints Helen Collins, Md, to Its Board of Directors

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

New minor risk - Share price stability

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Price target decreased by 15% to US$9.67

IO Biotech, Inc. Appoints Heidi Hunter to Its Board of Directors

IO Biotech, Inc. announced that it expects to receive $75.057935 million in funding from a group of investors

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center

IO Biotech, Inc. Announces Executive Changes

New minor risk - Share price stability

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech, Inc. Appoints Christine Richter as Senior Vice President, Commercial and Program Lead

Chief Financial Officer recently bought US$58k worth of stock

IO Biotech Appoints Devin Smith as General Counsel and Chief Compliance Officer

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Price target decreased to US$17.50

IO Biotech, Inc. Announces Appointment of Amy Sullivan as Chief Financial Officer

IO Biotech names new CFO

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech GAAP EPS of -$0.64

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

IO Biotech, Inc. Announces Executive Changes

High number of new directors

High number of new directors

IO Biotech, Inc. Announces its Two Directors Not Stand for Re-Election

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

IO Biotech, Inc. Announces Appointment of David V. Smith to Board of Directors

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş